Sort by
Refine Your Search
-
Listed
-
Country
-
Program
-
Employer
- Umeå University
- Northeastern University
- University of Washington
- Josep Carreras Leukaemia Research Institute (IJC)
- Nencki Institute of Experimental Biology
- University of Minnesota
- Harvard University
- University of British Columbia
- University of Maryland, Baltimore
- University of Michigan
- University of North Carolina at Chapel Hill
- Wageningen University & Research
- ARDITI - Agência Regional para o Desenvolvimento da Investigação Tecnologia e Inovação
- Baylor College of Medicine
- Columbia University
- Fundació Hospital Universitari Vall d'Hebron- Institut de recerca
- Ghent University
- Heidelberg University
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- Indiana University
- Instituto de Tecnologia Química e Biológica António Xavier ITQB NOVA
- KU LEUVEN
- Missouri University of Science and Technology
- Oak Ridge National Laboratory
- Research Center for Molecular Medicine (CeMM), ÖAW
- Rutgers University
- Stanford University
- The International Institute of Molecular Mechanisms and Machines Polish Academy of Sciences
- The Jiang Lab, The Icahn School of Medicine at Mount Sinai
- The University of North Carolina at Chapel Hill
- The University of South Dakota
- UNIVERSITY OF HELSINKI
- UNIVERSITY OF MELBOURNE
- University College Cork
- University Hospital Magdeburg
- University of Alabama at Birmingham
- University of British Columbia Department of Surgery
- University of Colorado
- University of Illinois
- University of Utah
- University of York
- Université de Strasbourg
- Washington University in St. Louis
- 33 more »
- « less
-
Field
-
in plant breeding? The recent approval by the European Parliament of new legislation to allow application of gene editing approaches in plant breeding, offers new opportunities to address this. One
-
. About Intellia Intellia Therapeutics is a Cambridge-based biotechnology company focused on developing clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies
-
The successful candidate will be expected to lead the section of the project in relation to gene editing in insects, including micro-injection delivery methods and molecular aspects of detecting edits, to make
-
genetics, gene therapy, CRISPR-based gene editing, stem cell technologies, and translational disease modelling. We are particularly interested in developing treatments for retinal disorders prevalent in
-
Therapeutics is a Cambridge-based biotechnology company focused on developing clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies to transform lives of people with
-
. Previous experience with molecular biology techniques (Western blots, qPCR/RNAseq), experience with gene editing(CRISPR), and DNA manipulation, are all preferred. The candidate should have hands
-
: Experimental research - 90% Writing papers - 10% Required Qualifications: Skills in molecular biology experiments, cloning, and gene editing, ribosome purification Qualifications Required Qualifications: PhD
-
aging and aging-associated diseases. We use a combination of models (e.g. C. elegans, mouse, iPSCs) and techniques (e.g. gene editing, nanobody generation, small molecule screens) to identify, assess, and
-
disorders and aggressive cancers. Experimental approaches to be applied will include culture and transfection/infection of mammalian cell lines including CRISPR gene editing, protein structure function
-
, immunoblotting, ELISA, cloning and vector construction, CRISPR-based gene editing) and cellular assays (primary and tumor cell culture, bacterial culture, co-culture and immune functional assays, flow cytometry